Clopidogrel Tablet
Product Images NDC 50090-6567

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-6567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

189 (Clopidogrel Fig 3)

A forest plot chart depicting subgroups with hazard ratios comparing Clopidogrel versus placebo. The chart includes various subgroups such as Heparin/LMWH, Aspirin dose levels, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. It displays hazard ratios with 95% confidence intervals along a scale from 0.3 to 1.4, indicating relative risk favoring Clopidogrel or placebo within each subgroup.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A horizontal bar chart titled 'Effect on active metabolite AUC Mean and 90% confidence interval' showing the change relative to Clopidogrel administered alone. It compares the effects of co-administered proton pump inhibitors (PPIs) including Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on Clopidogrel's active metabolite area under the curve (AUC). The x-axis ranges from 0.4 to 1.4, indicating relative change values.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

A line graph displaying cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two groups are compared: placebo (+ aspirin) and clopidogrel (+ aspirin), with the clopidogrel group showing lower event rates. The p-value for the difference is 0.00009, indicating statistical significance.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A Kaplan-Meier survival curve showing the percentage of patients who died before first discharge over 28 days after randomization. The graph compares two groups: placebo and Clopidogrel, indicating 1845 deaths (8.1%) for placebo and 1726 deaths (7.5%) for Clopidogrel, with a 7% proportional risk reduction (p=0.03). The x-axis represents days since randomization and the y-axis shows percentage dead before discharge.*

FDA Label Image

146 (Clopidogrel Figure 05)

A cumulative incidence plot showing percentage of patients with death, reinfarction, or stroke up to 28 days since randomization for Clopidogrel versus placebo. The graph compares event rates over time, indicating a lower proportional risk for Clopidogrel compared to placebo.*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines represent aspirin and clopidogrel, with clopidogrel demonstrating a slightly lower cumulative event rate compared to aspirin. A p-value of 0.045 is noted on the graph.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot displaying hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel to placebo. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, showing the relative favorability of Clopidogrel versus placebo across these categories.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot showing odds ratios with 99% confidence intervals comparing Clopidogrel versus placebo across demographic and clinical subgroups including gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot visually indicates which treatment was favored in each subgroup and overall outcomes.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot comparing Clopidogrel versus Aspirin showing hazard ratios with 95% confidence intervals for different qualifying conditions: stroke, myocardial infarction (MI), peripheral artery disease (PAD), and overall. The x-axis represents the hazard ratio ranging from 0.6 to 1.3, indicating relative favoring of Clopidogrel or Aspirin for the specified conditions.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of Clopidogrel, showing its molecular composition including sulfur-containing thienopyridine ring, ester group, chlorine-substituted aromatic ring, and associated sulfuric acid molecule (H2SO4).*

FDA Label Image

Label Image (Lbl500906567)

Label for Clopidogrel 75 mg oral tablets, manufactured by A-S Medication Solutions. The label specifies each tablet contains 97.85 mg of clopidogrel bisulfate, equivalent to 75 mg of clopidogrel base. The package contains 30 tablets with storage instructions to keep at 60 to 70 degrees Fahrenheit. Includes NDC 50090-6567-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.